Addressing unmet needs in rare diseases and systemic complement mediated disorders

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenienc

A leader in the field of engineered protease biopharmaceuticals

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Protease engineering platform – hemophilia assets in development and a SQ systemic complement research program

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Next Generation Protease Drugs

Learn more about our Pipeline

SQ Marzeptacog alfa (activated) “MarzAA”
Hemophilia A or B w Inhibitors – ToB
Phase 3
SQ Marzeptacog alfa (activated) “MarzAA”
FVIID/Glanzmann/Hemlibra – ToB
Phase 1/2
IVT CB 2782-PEG
Anti-C3 protease for Dry AMD
Preclinical
SQ CB 4332
 
Preclinical
C4b Degrader
 
Preclinical
Additional Programs
 
Preclinical
SQ Dalcinonacog alfa “DalcA”
Hemophilia B (rFIX)
Phase 2
FIX-Gene Therapy
Hemophilia B FIX Gene Therapy
Preclinical

Protease Engineering Platform

 

Late-Stage Asset

SQ Marzeptacog alfa (activated)
MarzAA (FVIIa)

Phase 3

 

Complement

CB 2782-PEG

IVT Anti-C3 Dry AMD

CB 4332 SQ Enhanced CFI

SQ Systemic Complement Degraders

Hemostasis

SQ MarzAA (FVIIa)

SQ Dalcinonacog alfa – DalcA (FIX)

Factor IX Gene Therapy

Factor Xa

 

Protease Medicines

The Catalyst Advantage

Drug candidates for severe medical conditions

Learn more about the medicines we are developing

See our pipeline

Addressing diseases with unmet medical needs

Share our passion about treating disease

See our publications 

Experienced and passionate team

Learn more about the Catalyst team and mission/culture

Meet the team